Related Experiment Video

Updated: Apr 11, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

16.0K

BRAF inhibitor plus rituximab in classical hairy cell leukaemia: A retrospective multicentre real-life study

Urbain Tauveron-Jalenques1, Luca Inchiappa2, Jérôme Paillassa3

  • 1Cellular Therapy and Clinical Hematology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

British Journal of Haematology
|April 10, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
BRAF V600EBRAF inhibitordabrafenibhairy cell leukaemiarituximabvemurafenib

More Related Videos

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

4.1K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.4K

Related Experiment Videos

Last Updated: Apr 11, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

16.0K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

4.1K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

Articles linked to this work by shared authors, journal, and citation graph.

Abatacept as maintenance therapy in kidney transplantation: a retrospective comparative study.

Transplant international : official journal of the European Society for Organ Transplantation·2026

Plasma proteomics for prognostic stratification in newly diagnosed primary central nervous system lymphoma.

Neuro-oncology·2026

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups.

British journal of haematology·2026

Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk-Stratification, and Treatment.

American journal of hematology·2026

Long-term results of brentuximab vedotin and bendamustine for first-line treatment of Hodgkin lymphoma in the elderly (HALO trial).

British journal of haematology·2026

Pharmaceutical interventions in self-medication: A descriptive study in community pharmacies.

Exploratory research in clinical and social pharmacy·2026

Outcome heterogeneity in CALR-mutated myeloproliferative neoplasms.

British journal of haematology·2026

Warm autoimmune haemolytic anaemia in Taiwan: A population-based study of epidemiology, treatment patterns, survival and healthcare utilisation (2017-2022).

British journal of haematology·2026

Clinical outcome and infectious complications in genetic and suspected genetic neutropenia: A report from the Canadian Inherited Marrow Failure Registry.

British journal of haematology·2026

SENIOR-IPI: An easily applicable prognostic index for first-line large B-cell lymphomas patients >80 years treated with curative intent.

British journal of haematology·2026

CALR-mutated myeloproliferative neoplasms: Refining molecular risk beyond the driver.

British journal of haematology·2026

RESOLVE to do better.

British journal of haematology·2026

Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack-Free Probability and Quality of Life Over 5 Years.

Clinical and translational science·2026

Adjuvant Systemic Hypothermia During Mechanical Thrombectomy (ReCCLAIM II): A Multicenter, Randomized, Controlled Trial.

Stroke·2026

Repeated Thrombolysis Using Tenecteplase in a Patient With Early Recurrent Ischaemic Stroke.

Cureus·2026

Blood Unit Discard Rates Due to Transfusion-Transmissible Infections and Non-Infectious Causes and Their Associated Factors in Eastern and Northeastern Parts of Amhara Regional State, Ethiopia: A Retrospective Cross-Sectional Study From 2022-2025.

Health science reports·2026

Sex differences in risk factors, stroke etiology, treatment characteristics, and outcomes after endovascular treatment for anterior circulation ischemic stroke.

Frontiers in stroke·2026

Dose-response relationship between tea consumption and mortality, cardiovascular, cerebrovascular, and renal outcomes in metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.

Frontiers in nutrition·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us